Atenolol
tablet
Composition
Each tablet contains
Atenolol ………………………………… 50 mg or 100 mg
Pharmacology
BETABLOK® is a cardio-selective beta-adrenergic receptor blocking agent without membrane-stabilizing or intrinsic sympathomimetic activities. After oral administration, absorption of BETABLOK® is rapid and consistent but only approximately 50. Peak plasma levels are reached between 2 - 4 hours after ingestion.
The elimination half-life is approximately 6 - 7 hours.
BETABLOK" is practically not metabolized by the liver and the absorbed portion is eliminated primarily by renal excretion. Therefore, clearance of this drug is closely related to the patient renal function, and accumulation occurs when the creatinine clearance falls below 35 mL/minute.
The beta-blocking effect of BETABLOK® is apparent within 1 hour after oral administration; this effect is maximal at about 2 - 4 hours, and persists for at least 24 hours.
Given as a single daily dose. BETABLOK® is an effective antihypertensive agent providing 24 hours reduction of blood pressure.
Increasing the dose beyond 100 mg once daily is not associated with increased antihypertensive effect.
In combination with thiazide diuretics, the antihypertensive effects of the combination are approximately additive.
Combination with methyldopa, hydralazine or prazosin results in a larger fall in blood pressure than with the single agents. Prolonged use of BETABLOK® does not show any diminution of its antihypertensive efficacy.
Indications
- Management of hypertension, alone or in combination with other antihypertensive
agents, particularly a thiazide diuretic. - Long - term management of chronic stable angina pectoris.
- sinus bradycardia
- 2nd and 3rd degree heart block
- cardiogenic shock
- over cardiac failure.
Precautions
- Bronchospastic diseases: use only in patients who do not respond to. or cannot tolerate. other antihypertensive treatment. Use the lowest possible dose and a beta 2 - stimulating agent (bronchodilator) should be available.
- Cardiac failure : use only in CHF controlled by digitalis and diuretics.
- May produce cardiac failure : if CHF continues despite adequate digitalization and diuresis, withdraw BETABLOK®
- Ischaemic heart disease . if cessation of therapy is desired, should be done slowly with limitation of physical activity.
Reinstate drug if withdrawal symptoms occur - Anesthesia and major surgery: withdraw drug before surgery or use with caution when using anesthetic agents which depress the myocardium such as ether, cyclopropane or thrichloroethylene.
- Diabetes and hypoglycemia : tachycardia occurring with hypoglycemia may be masked
- Thyrotoxicosis : certain clinical signs (e.g. tachycardia) maybe masked. Abrupt withdrawal may precipitate a thyroid storm.
- Impaired renal function : use tower doses (see 'Dosage').
- Drug interaction with :
- reserpine: may produce additive and thus excessive effects
- clonidine : if cessation of therapy is desired, withdraw BETABLOK® several days before the gradual withdrawal of clonidine.
- Pregnancy : use only if the potential benefit justifies the potential risk to the foetus
(fetal resorptions in rats). - Nursing mothers : nursing is not undertaken while taking the drug.
- Children : safety and effectiveness have not been established.
Dosage
- Hypertension: the initial dose is 50 mg as one tablet a day, alone or added to diuretic therapy. If a satisfactory response is not achieved in 1 - 2 weeks, the dosage should be increased to 100 mg as one tablet a day. Increasing the dosage beyond 100 mg a day is unlikely to produce any further benefit.
BETABLOK® may be used alone or concomitantly with other antihypertensive agents including thiazide diuretics, hydralazine, prazosin. or methyldopa. - Angina of effort: the dosage is 50 mg or 100 mg as one tablet a day. Increasingthe dose beyond 100 mg a day is not associated with increased effectiveness.
In patients with renal impairment, the following maximum dosages are recommended:Creatinine clearance Maximum dosage › 35 mL/minute 100 mg daily 15 - 35 mL/min 50 mg daily ‹ 15 mL/min 50 mg every other day
Patients undergone an haemodialysis should be given 50 mg after each dialysis,
and this should be done under hospital supervision.
Most adverse reactions are mild and transient. These include bradycardia. cold extremities, dizziness, tiredness, lethargy, drowsiness, vertigo, light headedness, depression, nausea, diarrhoea, skin rashes and/or dry eyes.
Presentation
BETABLOK® 50 mg : Box of 3 strips x 10 tablets. Reg. No. DKL8511603210A1
BETABLOK® 100 mg : Box of 3 strips x 10 tablets. Reg. No DKL8511603210B1
Store below 30°C.
ON MEDICAL PRESCRIPTION ONLY.
HARUS DENGAN RESEP DOKTER.
PT KALBE FARMA Tbk.
Bekasi - Indonesia
0 Komentar
Penulisan markup di komentar